LOS ANGELES, Calif., April 23, 2013 — Andrew Ritter, president and CEO of Ritter Pharmaceuticals, Inc., was selected as a finalist for the third annual Healthcare Leadership Awards recently presented by The Los Angeles Business Journal.   Andrew has been at the forefront of researching the physiological effects of lactose intolerance and has gathered the leading minds in the fields of gastroenterology and biological science to put the technology behind colonic adaptation to work against the condition.  Andrew’s leadership at Ritter Pharmaceuticals has positioned the company at the forefront of developing therapeutic treatments based on colonic adaptation which alters the microflora for digestive health benefits.  Ritter’s lead product is being developed to treat lactose intolerance.

The LA Business Journal honored their award recipients and finalists at a banquet on Thursday, April 18 and featured them in a special supplement to the publication, released on April 22.  Andrew was recognized in the Research Executive category for his commitment to advancing the standard of lactose intolerant patient care by working to provide what may be the first medical treatment option for the more than 40 million Americans who suffer with mild to severe lactose intolerance.

“I am honored that the Los Angeles Business Journal’s Awards committee has named me among the healthcare leaders in Los Angeles,” said Andrew Ritter.  “And, I applaud the Journal for acknowledging the important role that medical research has on our local economy and citizens,” he added.

Ritter Pharmaceuticals

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem.  Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development.  Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance.

Media Contact:
Susan Rogers
susan@ritterpharma.com
650-430-3777

LOS ANGELES, Calif., April 17, 2013 – According to a recent survey, eight out of ten people with mild to severe Lactose Intolerance (LI) are compelled to modify their diets and other daily activities in an effort to manage or forestall the symptoms of their disorder. Patients report that even with dietary changes many of them continue to experience symptoms, with 90% reporting that they have symptoms at least once per week and 50% have symptoms multiple times per week. When asked how LI impacts their lifestyles, patients said they go out less frequently and worry about being in public places in the event that symptoms should flare.

“Before I figured out that I couldn’t process dairy foods, I was running to the bathroom all the time,” said Lissa (full name withheld for privacy), a corporate product specialist and lactose intolerant patient. “It has been a slow process of modifying my diet to be able to go to work, out with friends, and more. I have even lied about not liking pizza to keep from getting sick,” she added.
The survey was conducted by an independent research firm, Objective Insights, and included 1,000 patients with mild to severe LI and more than 30 physicians who treat patients with this disorder. Lactose Intolerance occurs when a person does not have adequate amounts of the enzyme lactase in their intestinal tract to properly digest lactose, which is a complex sugar found in milk and milk-containing products. Symptoms range from mild to severe abdominal cramping, bloating, gas and diarrhea.

Lissa says she reads every label and turns away food at restaurants that she suspects has dairy in it. “If I am eating out, I have to avoid any meal that’s complex. There are times I watch other people enjoy foods that I could only dream of enjoying.” In addition to being very painful physically, Lissa says being Lactose Intolerant causes her to have “embarrassing side effects”.

While many over the counter remedies and lactose free dairy products are marketed to provide dietary options, many LI patients report that those options are largely unsatisfactory, especially when dining out at restaurants or travelling. More research is needed to develop a treatment that would enable LI patients to consume dairy products without the symptoms they dread. Ritter Pharmaceuticals has conducted extensive research into understanding lactose intolerance and is committed to providing an effective therapy which may one day restore freedom of food choices to LI patients.

Ritter Pharmaceuticals (www.ritterpharmaceuticals.com)
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development. Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and may well be the first medical option available to LI patients some day.

For additional information contact:
Susan Rogers
650-430-3777
susan@ritterpharma.com

According to Ritter’s Chief Medical Officer, Larry Good, M.D., “The FDA provided us very helpful guidance on our clinical development plans. We now have a clear understanding of the FDA’s expectations and our path forward with our investigational agent, RP-G28.”

Ritter expects to begin advanced Phase 2 clinical trials in patients with Lactose Intolerance later this year.

Ritter Pharmaceuticals

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem.  Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development.  Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and may well be the first medical option available to LI patients some day.

Media Contact:
Susan Rogers
susan@ritterpharma.com
650-430-3777

“Dr. Good’s appointment to the lead research and development role at Ritter acknowledges his contributions to our R&D team to date, and will provide valuable expertise as we advance our clinical programs,” said Andrew Ritter, president and chief executive officer of Ritter Pharmaceuticals.

“Ritter’s approach to treating lactose intolerance and other GI disorders through colonic adaptation has the potential to change how these disorders are treated in the future,” said Dr. Good.  “I look forward to overseeing future R&D at Ritter, including advanced clinical study design and implementation,” he added.

Larry Good, M.D.

Dr. Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012. Dr. Good is nationally recognized for his clinical experience with clostridium difficile and has conducted extensive clinical research in a range of GI specialties, including biliary lipid metabolism, irritable bowel syndrome and inflammatory bowel disease. Dr. Good received his M.D. from the Medical University of South Carolina and was Chief Resident in Medicine. He was a Fellow in Gastroenterology at the University of Pennsylvania. Dr. Good has publications in prestigious peer review journals including The New England Journal Of Medicine, Gastroenterology and the American Journal of Gastroenterology. He has been recognized by Who’s Who in Medicine and Science, has been selected as one of America’s Top Gastroenterologists by the Consumers’ Research Council of America and has received the Golden Apple Award for excellence in medical teaching by the American Medical Student Association.

Lactose Intolerance

Lactose Intolerance is a common condition attributed to insufficient levels of the enzyme lactase which is needed to properly digest lactose, a complex sugar found in milk and milk containing foods.  People with lactose intolerance who ingest lactose-containing foods may experience pain and other symptoms which may limit their diet and cause embarrassment.  The condition is prevalent worldwide, where it is estimated that more than 1 billion people may be lactose intolerant.  To date, no medical treatment is available to help those who suffer with this condition.

Ritter Pharmaceuticals   (www.ritterpharmaceuticals.com)

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem.  Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development.  Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and may well be the first medical option available to LI patients some day.

For additional information contact:

Susan Rogers
650-430-3777
susan@ritterpharma.com

Los Angeles, Calif., January 30, 2013 – -  A recent survey of patients with Lactose Intolerance revealed that more than three fourths of them reduce or eliminate dairy from their diets as the primary means of “managing” their symptoms.  What’s more, a majority (56%) of them worry about the long-term risks to their health due to this dietary restriction.

The survey, conducted by Objective Insights, an independent research firm, included 1,000 patients with mild to severe Lactose Intolerance (LI) and 40 physicians (gastroenterologists and primary care physicians).   The impact of Lactose Intolerance on patients, the role of the physician and patient in diagnosing and managing the condition, and the perceived effectiveness of currently available remedies were among the lead topics surveyed.

“There is a high level of awareness in the medical community that managing the symptoms of Lactose Intolerance by dairy avoidance is an unsatisfactory treatment approach for two reasons;  First, it is difficult to completely avoid dairy and, second, because doing so may result in calcium and vitamin D deficiencies,” said Larry Good, M.D. former Chief Gastroenterologist at South Nassau Communities Hospital in Oceanside, N.Y.  Dr. Good also noted that, “calcium supplements and non dairy substitutes are generally inadequate in meeting dietary calcium requirements in otherwise healthy individuals.”

Further acknowledgement of the significance of this subject comes from The National Institutes of Health, which, for the first time, in 2010, gathered a consortium of experts to consider it.  The NIH Conference conclusions stated the need for research on potential therapeutic interventions for Lactose Intolerance, in part, because “Lactose Intolerance is a real and important clinical syndrome” and many patients with LI “avoid dairy and ingest inadequate amounts of calcium and vitamin D, which may predispose them to decreased bone accrual, osteoporosis, and other adverse health outcomes.”

“Patients shouldn’t have to trade off one set of health concerns for another,” said Dennis Savaiano, Ph.D., Professor of Nutrition Science at Purdue University and Chair of Ritter Pharmaceuticals’ Medical Advisors, whose investigational drug, RP-G28 is in mid stage clinical research for treating lactose intolerance. “Patients who avoid milk have lower calcium intakes and typically lower bone density — a strong risk factor for osteoporosis.  Dairy avoidance is not the appropriate method of managing these patients” he added.

-

Lactose Intolerance

Lactose Intolerance is a common condition attributed to insufficient levels of the enzyme lactase which is needed to properly digest lactose, a complex sugar found in milk and milk containing foods.  People with lactose intolerance who ingest lactose-containing foods may experience pain and other symptoms which may limit their diet and cause embarrassment.  The condition is prevalent worldwide, where it is estimated that more than 1 billion people may be lactose intolerant.  To date, no medical treatment is available to help those who suffer with this condition.

Ritter Pharmaceuticals   (www.ritterpharmaceuticals.com)

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem.  Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development.  Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and may well be the first medical option available to LI patients some day.

For additional information contact:    Susan Rogers

650-430-3777

susan@ritterpharma.com

(http.//consensus.nih.gov/2010/lactosestatement.htm.)

LOS ANGELES, Calif. – January  7, 2012 –  Nearly 40 million Americans are lactose intolerant and must significantly limit – or avoid – milk and dairy products, or suffer with embarrassing and debilitating gastrointestinal pain.  Despite the availability of lactose-free food options and over the counter remedies, a recent study by Objective
Insights reported that 45% of patients with Lactose Intolerance (LI) do not find effective relief with these options, and 70% of them claim that a more reliable and medically sound alternative is needed.

Ritter Pharmaceuticals is developing the first prescription drug candidate for LI and has completed a Phase 2 clinical study aimed at evaluating the drug candidate’s potential benefits for LI patients.  Ritter’s drug candidate, RP-G28, is a non-digestible carbohydrate used to stimulate colonic growth of lactose-fermenting bacteria in the large intestine.  The study results showed proof-of-concept that RP-G28 was safe and well tolerated and, most notably, improved lactose digestion and reduced lactose intolerance symptoms in LI patients.  In addition, the favorable results from this study support further investigation of RP-G28 and provide valuable information for the design of the future clinical studies.

Phase 2 Study of RP-G28 for Lactose Intolerance

The double-blinded, randomized, multi-center, placebo-controlled Phase 2 study of 62 patients evaluated RP-G28 in lactose intolerant patients over a treatment period of 35 days and at 30 days post-cessation of treatment.  The primary endpoints included tracking patients’ gastrointestinal symptoms via a Likert Scale at baseline, day 36 and day 66; as well as the measurement of hydrogen gas levels in their breath following a lactose challenge.  Statistically significant results reported that 30 days after completion of a single treatment cycle, 6 times as many patients in the treatment group versus the placebo group reported lactose tolerance – the ability to consume dairy products again without symptoms.  The patients in the RP-G28 treatment group reported overall reduction in symptoms, including reduction in abdominal pain, abdominal cramping, bloating and flatulence at day 36.  In addition, the treated patient group had a greater reduction in hydrogen gas production compared with the placebo group post-treatment.  RP-G28 appears to be an effective strategy for improving lactose digestion and reducing lactose intolerance symptoms in LI subjects.  Ritter expects to report the complete results from this Phase 2 clinical study in a peer-reviewed journal.

“These results show that RP-G28 may one day allow lactose intolerant patients the freedom to consume dairy foods again without experiencing embarrassing and painful GI symptoms,” said Andrew J. Ritter, president and CEO of Ritter Pharmaceuticals, Inc.   “We anticipate that the next clinical study evaluating RP-G28 will begin later this year,” he added.

Lactose Intolerance

Lactose Intolerance is a common condition attributed to insufficient levels of the enzyme lactase which is needed to properly digest lactose, a complex sugar found in milk and milk containing foods.  People with lactose intolerance who ingest lactose-containing foods may experience painful and embarrassing digestive symptoms. The condition is prevalent worldwide, where it is estimated that more than 1 billion people may be lactose intolerant.  To date, no medical treatment is available to help those who suffer with this condition.

Ritter Pharmaceuticals

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem.  Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research and development.  Ritter’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and continues to be developed as a potential medical therapy for patients with LI.

For additional information contact:
Susan Rogers
650-430-3777
susan@ritterpharma.com

“We are pleased to have Mike join Ritter Pharma’s Board of Directors,” said Ritter Pharma’s President and Chief Executive Officer, Andrew Ritter. “Mike’s enthusiasm and forward thinking will add a unique perspective to help drive our strategic path forward. We are looking forward to Mike’s participation and his valuable guidance.”

Mr. Step commented, “I am appreciative of the opportunity to join Ritter Pharmaceuticals’ Board of Directors. The company is well positioned having just completed a successful Phase 2 clinical trial for a lactose intolerance treatment, and I look forward to being a part of the future at Ritter Pharma.”

In addition to his position on the board, Mr. Step is the Senior Vice President of Corporate Development at Santarus. Prior to joining Santarus, he was Vice President, Corporate Development for Amylin Pharmaceuticals and Senior Director, Business Development at Dura Pharmaceuticals. In these roles, he was primarily responsible for leading corporate development activities, including product licensing, strategic planning, and mergers and acquisitions evaluations. Mr. Step holds a B.A. in political science from Vanderbilt University and an M.B.A. from the University of Southern California.

About RP-G28

RP‐G28 has the potential to become the first FDA‐approved drug for the treatment of lactose intolerance. RP‐G28 is a proprietary oligosaccharide that is orally administered for a set treatment period. The effect of RP-G28 is to induce a change in colon microbe populations which enables lactose digestion. After a single treatment cycle, patients experience a sustained ability to consume dairy products.

About Lactose Intolerance

Lactose intolerance is a common gastrointestinal condition often causing debilitating and painful symptoms from the consumption of dairy products. Globally, over 1 billion people are lactose intolerant, 39 million of whom are estimated to live in the United States. People with lactose intolerance have insufficient lactase, the enzyme lining the small bowel and responsible for breaking down lactose (“milk sugar”). The result is one or more gastrointestinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.

About Ritter Pharmaceuticals, Inc

Ritter Pharma is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Ritter Pharma is rapidly establishing itself as a world’s leader in lactose intolerance research. For additional information, please visit www.RitterPharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of Ritter’s drug candidate, RP-G28, and RP-G28′s potential to treat the symptoms associated with lactose intolerance.  Words such as “intended”, “potential” and similar words and expressions identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Ritter that any of its plans will be achieved. Future results can be affected by inaccurate assumptions and by known or unknown risks and uncertainties. For example, statements relating to Ritter’s ongoing clinical trials may turn out to be wrong because, among other things, Ritter’s product candidates may prove to be ineffective and planned studies could be delayed as a result of actions by third parties upon whom Ritter relies or Ritter’s own lack of financial resources. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ritter undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

For more information contact:
Justin Chandler
Media Relations
Justin@RitterPharma.com
310-203-1000

The abstract was presented by Dennis Savaiano, Ph.D., who is the chairman of Ritter’s Medical Advisory Board and Professor of Nutrition Science at Purdue University. The presentation discussed the importance of a lactose intolerance treatment and highlighted Ritter’s Phase 2 clinic on RP-G28 which demonstrated that RP-G28 improves digestive symptoms associated with lactose intolerance while changing the intestinal bacterial population and reducing breath hydrogen production (a commonly used diagnostic test for lactose maldigestion).

“I am pleased to have the opportunity to discuss and share clinical trial results on RP-G28,” said Dennis Savaiano. “Proving mechanism of action for a treatment for lactose intolerance is an exciting accomplishment.”

This study marks a major milestone in lactose intolerance research as it represents the first controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.

“Presenting at DDW 2012 in front of the gastrointestinal community was a great opportunity for our company and for RP-G28,” said Andrew Ritter, President and CEO of Ritter Pharmaceuticals. “The results provide evidence that RP-G28 is a potentially condition-modifying treatment, in that the symptom reduction and the changes in bacterial population persisted for a month after stopping drug treatment.”

About RP-G28
RP‐G28 has the potential to become the first FDA‐approved drug for the treatment of lactose intolerance. RP‐G28 is a proprietary oligosaccharide that is orally administered for a set treatment period. The effect of RP-G28 is to induce a change in colon microbe populations which enables lactose digestion. After a single treatment cycle, patients experience a sustained ability to consume dairy products.

About Lactose Intolerance
Lactose intolerance is a common gastrointestinal condition often causing debilitating and painful symptoms from the consumption of dairy products. Globally, over 1 billion people are lactose intolerant, 39 million of whom are estimated to live in the United States. People with lactose intolerance have insufficient lactase, the enzyme lining the small bowel and responsible for breaking down lactose (“milk sugar”). The result is one or more gastrointestinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.

About Ritter Pharmaceuticals, Inc
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Ritter is rapidly establishing itself as a world’s leader in lactose intolerance research. For additional information, please visit www.RitterPharma.com.

For more information contact:

Justin Chandler
Media Relations
Justin@RitterPharma.com
310-203-1000

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of Ritter’s drug candidate, RP-G28, and RP-G28′s potential to treat the symptoms associated with lactose intolerance. Words such as “intended”, “potential” and similar words and expressions identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Ritter that any of its plans will be achieved. Future results can be affected by inaccurate assumptions and by known or unknown risks and uncertainties. For example, statements relating to Ritter’s ongoing clinical trials may turn out to be wrong because, among other things, Ritter’s product candidates may prove to be ineffective and planned studies could be delayed as a result of actions by third parties upon whom Ritter relies or Ritter’s own lack of financial resources. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ritter undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Dennis Savaiano, Ph.D., chairman of Ritter’s Medical Advisory Board and Professor of Nutrition Science at Purdue University, will make the presentation in San Diego, California on Tuesday, May 22 at 11:15 a.m. Pacific Time.

The DDW presentation describes the company’s recently announced Phase 2 study results, which demonstrate that treatment with RP‑G28 improves digestive symptoms associated with lactose intolerance and also reduces breath hydrogen production (a commonly used diagnostic test for lactose maldigestion).  These Phase 2 data provide evidence to support the proof of concept for RP-G28 as a treatment for the symptoms associated with lactose intolerance.

This study marks a major milestone in lactose intolerance research as it represents the first controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.

“Lactose intolerance is a very common condition representing a large unmet medical need,” said Andrew Ritter, President and CEO. “We are pleased to have the opportunity to share our Phase 2 results with the gastroenterology community at DDW 2012 and enthusiastic that our results further our development of this new therapy.”

About RP-G28

RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance.  RP‐G28 is an orally administered, proprietary oligosaccharide intended to alleviate the symptoms of lactose intolerance on a long-term basis and possibly impact the natural course of the disease.

About Lactose Intolerance

Lactose intolerance is a common gastrointestinal disease affecting nearly 60 million Americans and 2 out of 3 people worldwide. People with lactose intolerance have insufficient lactase, the enzyme lining the small bowel and responsible for breaking down lactose (“milk sugar”).  The result is one or more gastrointestinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.

About Ritter Pharmaceuticals, Inc

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance.  Ritter is rapidly establishing itself as a world’s leader in lactose intolerance research. For additional information, please visit www.RitterPharma.com.

For more information contact:

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of Ritter’s drug candidate, RP-G28, and RP-G28′s potential to treat the symptoms associated with lactose intolerance.  Words such as “intended”, “potential” and similar words and expressions identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Ritter that any of its plans will be achieved. Future results can be affected by inaccurate assumptions and by known or unknown risks and uncertainties. For example, statements relating to Ritter’s ongoing clinical trials may turn out to be wrong because, among other things, Ritter’s product candidates may prove to be ineffective and planned studies could be delayed as a result of actions by third parties upon whom Ritter relies or Ritter’s own lack of financial resources. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ritter undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

This study marks a major milestone in lactose intolerance research, as it represents the first adequate and well-controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.

Subjects in the RP-G28 group reported a reduction in total symptoms of 56 percent after treatment which increased to nearly a 70 percent reduction by 30 days post-treatment. Importantly, subjects had a statistically significant decrease in abdominal pain (p = 0.03) compared to those receiving placebo. The reduction in total symptoms was consistent with the improvement in hydrogen breath test results following post-treatment lactose challenge as compared to baseline (pre-treatment) results. Subjects treated with RP-G28 had a 15 percent greater decrease in hydrogen production as compared to those receiving placebo. RP-G28 was well tolerated with no significant study-drug related adverse events. Ritter Pharma plans to release the complete data set for the Phase 2 trial at an upcoming major medical meeting or in a peer-reviewed journal.

“We are very pleased with the results of our Phase 2 trial of RP-G28, demonstrating improvements in both lactose digestion and symptoms,” stated Andrew Ritter, Ritter Pharma’s president and chief executive officer. “These data will enable us to advance through late-stage clinical development in order to bring RP-G28 to the many patients suffering from inadequately treated lactose intolerance.”

“There are no effective or reliable long-term treatments currently available for those with lactose intolerance,” said Dennis Savaiano, Ph.D., professor of Foods and Nutrition and former dean at Purdue University, who is considered one of the world’s foremost experts on lactose intolerance. “With these strong results, RP-G28 has great potential to help millions of patients with lactose intolerance consume dairy products again.”

About RP-G28

RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. Treatment with RP-G28 stimulates colonic growth and helps to colonize the colon with lactose-fermenting bacteria, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance. RP-G28 stands out as the only therapeutic regimen impacting the natural history of the disease and alleviating the symptoms of lactose intolerance on a long-term basis.

About Lactose Intolerance

Lactose intolerance is a common gastrointestinal disease affecting over 80 million Americans and four billion people worldwide. People with lactose intolerance have a low activity level of lactase, the enzyme responsible for breaking down human lactose, resulting in one or more of the cardinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.

About Ritter Pharmaceuticals, Inc

Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter is rapidly establishing itself as the world’s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. For additional information, please visit www.RitterPharma.com.